Literature DB >> 23821285

Methods for evaluation of antiviral efficacy against influenza virus infections in animal models.

Donald F Smee1, Dale L Barnard.   

Abstract

Compounds undergoing preclinical development for anti-influenza virus activity require evaluation in small animal models. Laboratory mice are most commonly used for initial studies because of size, cost, and availability. Cotton rats, guinea pigs, and ferrets (particularly) have been used for more advanced studies. Each animal infection model has certain limitations relative to human influenza infections. For example, the fever response that is evident in humans only occurs with consistency in ferrets. Mice infected with mouse-adapted viruses and ferrets infected with highly pathogenic avian influenza viruses suffer severe disease, whereas cotton rats and guinea pigs manifest few symptoms. Thus, for each animal model there is a certain set of disease parameters that can be measured. Here we describe methods for assessing the efficacy of anti-influenza virus compounds in each of these animal species.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23821285     DOI: 10.1007/978-1-62703-484-5_31

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  7 in total

1.  Structure-Property Relationship Studies of Influenza A Virus AM2-S31N Proton Channel Blockers.

Authors:  Yanmei Hu; Raymond Kin Hau; Yuanxiang Wang; Peter Tuohy; Yongtao Zhang; Shuting Xu; Chunlong Ma; Jun Wang
Journal:  ACS Med Chem Lett       Date:  2018-10-03       Impact factor: 4.345

2.  Development of a respiratory disease model for enterovirus D68 in 4-week-old mice for evaluation of antiviral therapies.

Authors:  W Joseph Evans; Brett L Hurst; Christopher J Peterson; Arnaud J Van Wettere; Craig W Day; Donald F Smee; E Bart Tarbet
Journal:  Antiviral Res       Date:  2018-12-03       Impact factor: 5.970

3.  Serum amyloid A (SAA) is an early biomarker of influenza virus disease in BALB/c, C57BL/2, Swiss-Webster, and DBA.2 mice.

Authors:  Almut H Vollmer; Makda S Gebre; Dale L Barnard
Journal:  Antiviral Res       Date:  2016-08-11       Impact factor: 5.970

4.  Can animal data translate to innovations necessary for a new era of patient-centred and individualised healthcare? Bias in preclinical animal research.

Authors:  Susan Bridgwood Green
Journal:  BMC Med Ethics       Date:  2015-07-28       Impact factor: 2.652

Review 5.  Animal models for influenza virus pathogenesis, transmission, and immunology.

Authors:  Rajagowthamee R Thangavel; Nicole M Bouvier
Journal:  J Immunol Methods       Date:  2014-04-04       Impact factor: 2.303

Review 6.  Discovery and development of safe-in-man broad-spectrum antiviral agents.

Authors:  Petter I Andersen; Aleksandr Ianevski; Hilde Lysvand; Astra Vitkauskiene; Valentyn Oksenych; Magnar Bjørås; Kaidi Telling; Irja Lutsar; Uga Dumpis; Yasuhiko Irie; Tanel Tenson; Anu Kantele; Denis E Kainov
Journal:  Int J Infect Dis       Date:  2020-02-17       Impact factor: 3.623

7.  The Iminosugar UV-4 is a Broad Inhibitor of Influenza A and B Viruses ex Vivo and in Mice.

Authors:  Kelly L Warfield; Dale L Barnard; Sven G Enterlein; Donald F Smee; Mansoora Khaliq; Aruna Sampath; Michael V Callahan; Urban Ramstedt; Craig W Day
Journal:  Viruses       Date:  2016-03-07       Impact factor: 5.818

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.